» Articles » PMID: 20663900

Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell Line

Overview
Journal Cancer Res
Specialty Oncology
Date 2010 Jul 29
PMID 20663900
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

SNS-032 is a potent inhibitor of cyclin-dependent kinases (Cdk) 2, 7, and 9 that regulate the cell cycle and transcription. Our studies in indolent primary chronic lymphocytic leukemia cells showed that SNS-032 inhibited transcription, diminished the antiapoptotic protein Mcl-1, and induced apoptosis. The present study focuses on evaluating this compound in four proliferating mantle cell lymphoma lines (Jeko-1, Granta 519, Mino, and SP-53). Consistent with its action against Cdk9 and Cdk7, SNS-032 inhibited the phosphorylation of RNA pol II in all four lines and blocked RNA synthesis. The transcripts and protein levels of short-lived proteins decreased, including cyclin D1 and Mcl-1. Cell growth was inhibited in a concentration-dependent manner in all lines. Apoptosis was induced in JeKo-1, Mino, and SP-53 cells without disrupting cell cycle distribution. However, apoptosis was limited in Granta cells; rather, there was a significant reduction of clonogenic survival. Small interfering RNA was used to specifically knock down Mcl-1 and cyclin D1 in JeKo-1 and Granta cells. Knocking down Mcl-1 induced significant apoptosis in Jeko-1 cells but not Granta cells. Reducing cyclin D1, rather than Mcl-1, was associated with loss of clonogenic survival in Granta cells. Thus, these results indicated that mantle cell lymphoma cell lines have distinct mechanisms sustaining their survival, and the mechanism of action of SNS-032 is dependent on the biological context of an individual line.

Citing Articles

SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells inhibition of cyclin dependent kinase 9.

He X, Hu Y, Chen J, Zhang D, Yang H, Zhang L Front Pharmacol. 2022; 13:1016552.

PMID: 36313366 PMC: 9597511. DOI: 10.3389/fphar.2022.1016552.


A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells.

Ghaderi A, Zhong W, Okhovat M, Aschan J, Svensson A, Sander B Pharmaceutics. 2022; 14(10).

PMID: 36297673 PMC: 9607197. DOI: 10.3390/pharmaceutics14102238.


SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16.

Liu Y, Kong W, Yu C, Shao Z, Lei Q, Deng Y Acta Pharmacol Sin. 2022; 44(4):853-864.

PMID: 36261513 PMC: 10043269. DOI: 10.1038/s41401-022-01003-4.


Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells.

Jiang L, Wen C, Zhou H, Liu A, Zhang H, Chen X Cancer Biol Ther. 2022; 23(1):319-327.

PMID: 35332847 PMC: 8959513. DOI: 10.1080/15384047.2022.2055421.


Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms.

Albero R, Enjuanes A, Demajo S, Castellano G, Pinyol M, Garcia N J Clin Invest. 2018; 128(9):4132-4147.

PMID: 29990311 PMC: 6118591. DOI: 10.1172/JCI96520.


References
1.
Chen R, Gandhi V, Plunkett W . A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006; 66(22):10959-66. DOI: 10.1158/0008-5472.CAN-06-1216. View

2.
Williams M, Densmore J . Biology and therapy of mantle cell lymphoma. Curr Opin Oncol. 2005; 17(5):425-31. DOI: 10.1097/01.cco.0000174039.69656.2b. View

3.
Venkataraman G, Maududi T, Ozpuyan F, Bahar H, Izban K, Qin J . Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment. Leuk Res. 2006; 30(11):1377-84. DOI: 10.1016/j.leukres.2006.03.004. View

4.
Meng H, Yang C, Jin J, Zhou Y, Qian W . Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Leuk Lymphoma. 2008; 49(10):1954-62. DOI: 10.1080/10428190802320368. View

5.
Haritunians T, Mori A, OKelly J, Luong Q, Giles F, Koeffler H . Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2006; 21(2):333-9. DOI: 10.1038/sj.leu.2404471. View